Abstract: The invention is directed to methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy, which method comprises assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator. Antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids are also disclosed.
Abstract: The invention is directed to methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy, which method comprises assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator. Antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids are also disclosed.
Abstract: A carboxyterminal propeptide of type I procollagen free from type III procollagen carboxyterminal propeptide can be used to produce an antibody which is specific for carboxyterminal propeptide of type I procollagen and which has no affinity for the type III procollagen carboxyterminal propeptide. This antibody can be used to assay more accurately the propeptide which is a measure of the rate of production of type I procollagen and useful in diagnosing and monitoring e.g. bone diseases.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
December 16, 1997
Assignee:
Orion-Yhtyma OY
Inventors:
Juha Risteli, Leila Risteli, Jukka Melkko
Abstract: A method for separation of a mixture of biological entities into at least three distinct, subpopulations. Different antibodies are provided, with each antibody bound to a solid support in a unique manner such that by a manipulation of the physical or chemical environment, the bonds between the antibodies and the solid supports can be selectively broken. The mixed population of cells is incubated with the antibodies. The cells are magnetically separated from a test medium and collected in a monolayer upon a collection surface. Then by manipulation of the physicochemical environment, specific linkages can be broken and desired cell subpopulations released from the collection surface. This method has medically significant diagnostic and therapeutic applications, as entire cell types can be separated from non-malignant medically vital cell types. Cancer can be diagnosed, staged, and monitored. Genetic analysis from maternal blood, CVS, or amniocentesis samples is possible.
Type:
Grant
Filed:
February 28, 1995
Date of Patent:
July 8, 1997
Assignee:
Immunivest Corporation
Inventors:
Leon W. M. M. Terstappen, Galla C. Rao, Dhanesh I. Gohel, Brian P. Feeley, Steven Gross, Ellen S. Church, Paul A. Liberti
Abstract: A method for the direct analysis of analyte in keratinized structures, e.g., hair, fingernails and toenails, which comprises preparing a mixture containing a low redox potential compound such as dithiothreitol or dithioerythritol, an enzyme suitable for the degradation of the keratin structure and a sample of the keratin structure; permitting the enzyme to at least substantially degrade the sample of keratin structure, and subjecting the mixture to analysis to determine the identity and amount of analyte in the keratin substance sample. To accelerate the method, cupric sulfate or sodium arsenite may be added to the mixture after degradation of the keratin sample. The enzyme may be a peptidase, endopeptidase or proteinase, with papain, chymopapain, and proteinase K being preferred for use in the invention.
Abstract: An analyzer has a reaction disk for holding a plurality of reaction containers and a fluorophotometer for measuring fluorescence stemming from solutions in the containers. Most of the containers contain solid phases attached with antibodies but at least one container does not contain any solid phase. In normal operation of the analyzer, a test sample containing antigens and a latently fluorescent reagent such as an antibody labeled by an enzyme are added to a container containing a solid phase. In this container, a fluorescent substance is created through an enzyme reaction. Light is irradiated on the container and the fluorescence emitted from the fluorescent substance is measured. While measuring test samples, fluorescence stemming from a reference sample, such as quinine sulfate, is measured to produce values for the reference sample by which measured values for the test samples are corrected.